Vastatin - Vastatin is a hypolipidemic agent from a group of statins, an inhibitor of HMG-CoA reductase. This medication is a prodrug because it has in its structure the closed lactone ring which is hydrolyzed after intake.
Lipid-lowering effect of statins is associated with lower levels of total cholesterol by LDL-C. Reducing cholesterol is dose-dependent and is not linear but exponential. Statins do not affect the activity of lipoprotein and hepatic lipase, have no significant effect on the synthesis and catabolism of free fatty acids, thats why their effect on TG levels again and indirectly through their main effects on reducing LDL-C.
According to the controlled studies of simvastatin increases HDL-C to 14%.
In addition to the hypolipidemic actions Vastatin has beneficial effects in endothelial dysfunction (pre-clinical sign of early atherosclerosis), on the vascular wall, the state of atheroma, improves blood rheology, have antioxidant, antiproliferative properties. There is evidence that simvastatin improves endothelial function within 30 days of therapy.
Simvastatin therapy was accompanied by a decrease in the incidence of cardiovascular disorders, regardless of baseline LDL-C.
Simvastatin, (marketed under the trade names Zocor, Simlup, Simcard, Simvacor, and others, as well as generically) is a hypolipidemic drug belonging to the class of pharmaceuticals called "statins". It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus.
Vastatin helps lower your cholesterol level. Excessive cholesterol in your body can clog up your blood vessels. This can lead to many health problems such as strokes and heart disease, including heart attacks. Vastatin is meant to be taken as part of a complete cholesterol management programme that should include exercise, a healthy diet and lifestyle.
Adjunct to diet for treatment of hypercholesterolaemia. Patients at high risk of CHD (w/ or w/o hypercholesterolaemia) including diabetics, those w/ history of stroke or other CV disease, peripheral vessel disease, or w/ existing CHD to reduce the risk of CV death, major CV events including stroke, & hospitalisation due to angina pectoris.
Homozygous familial hypercholesterolaemia.